177 related articles for article (PubMed ID: 26834627)
61. Molecular characterization and measurement of Alzheimer's disease pathology: implications for genetic and environmental aetiology.
Wischik CM; Harrington CR; Mukaetova-Ladinska EB; Novak M; Edwards PC; McArthur FK
Ciba Found Symp; 1992; 169():268-93; discussion 293-302. PubMed ID: 1490426
[TBL] [Abstract][Full Text] [Related]
62. Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.
Pei JJ; Sjögren M; Winblad B
Curr Opin Psychiatry; 2008 Nov; 21(6):555-61. PubMed ID: 18852562
[TBL] [Abstract][Full Text] [Related]
63. Immunocytochemistry of neurofibrillary tangles with antibodies to subregions of tau protein: identification of hidden and cleaved tau epitopes and a new phosphorylation site.
Dickson DW; Ksiezak-Reding H; Liu WK; Davies P; Crowe A; Yen SH
Acta Neuropathol; 1992; 84(6):596-605. PubMed ID: 1281953
[TBL] [Abstract][Full Text] [Related]
64. Neuropathogenic role of adenylate kinase-1 in Aβ-mediated tau phosphorylation via AMPK and GSK3β.
Park H; Kam TI; Kim Y; Choi H; Gwon Y; Kim C; Koh JY; Jung YK
Hum Mol Genet; 2012 Jun; 21(12):2725-37. PubMed ID: 22419736
[TBL] [Abstract][Full Text] [Related]
65. Role of calpain and caspase in beta-amyloid-induced cell death in rat primary septal cultured neurons.
Wei Z; Song MS; MacTavish D; Jhamandas JH; Kar S
Neuropharmacology; 2008 Mar; 54(4):721-33. PubMed ID: 18222494
[TBL] [Abstract][Full Text] [Related]
66. Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach.
Iqbal K; Alonso AD; Gondal JA; Gong CX; Haque N; Khatoon S; Sengupta A; Wang JZ; Grundke-Iqbal I
J Neural Transm Suppl; 2000; 59():213-22. PubMed ID: 10961432
[TBL] [Abstract][Full Text] [Related]
67. Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers.
Anthony IC; Norrby KE; Dingwall T; Carnie FW; Millar T; Arango JC; Robertson R; Bell JE
Brain; 2010 Dec; 133(Pt 12):3685-98. PubMed ID: 21126996
[TBL] [Abstract][Full Text] [Related]
68. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.
Walton JR
J Inorg Biochem; 2007 Sep; 101(9):1275-84. PubMed ID: 17662457
[TBL] [Abstract][Full Text] [Related]
69. Phospho-Tau Changes in the Human CA1 During Alzheimer's Disease Progression.
Regalado-Reyes M; Furcila D; Hernández F; Ávila J; DeFelipe J; León-Espinosa G
J Alzheimers Dis; 2019; 69(1):277-288. PubMed ID: 30958368
[TBL] [Abstract][Full Text] [Related]
70. Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins).
Bramblett GT; Trojanowski JQ; Lee VM
Lab Invest; 1992 Feb; 66(2):212-22. PubMed ID: 1735956
[TBL] [Abstract][Full Text] [Related]
71. Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic mice and Alzheimer disease.
Pérez M; Morán MA; Ferrer I; Avila J; Gómez-Ramos P
Acta Neuropathol; 2008 Oct; 116(4):409-18. PubMed ID: 18679696
[TBL] [Abstract][Full Text] [Related]
72. Cytoskeletal pathology in non-Alzheimer degenerative dementia: new lesions in diffuse Lewy body disease, Pick's disease, and corticobasal degeneration.
Dickson DW; Feany MB; Yen SH; Mattiace LA; Davies P
J Neural Transm Suppl; 1996; 47():31-46. PubMed ID: 8841955
[TBL] [Abstract][Full Text] [Related]
73. Role of protein kinase B in Alzheimer's neurofibrillary pathology.
Pei JJ; Khatoon S; An WL; Nordlinder M; Tanaka T; Braak H; Tsujio I; Takeda M; Alafuzoff I; Winblad B; Cowburn RF; Grundke-Iqbal I; Iqbal K
Acta Neuropathol; 2003 Apr; 105(4):381-92. PubMed ID: 12624792
[TBL] [Abstract][Full Text] [Related]
74. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease.
Guillozet-Bongaarts AL; Garcia-Sierra F; Reynolds MR; Horowitz PM; Fu Y; Wang T; Cahill ME; Bigio EH; Berry RW; Binder LI
Neurobiol Aging; 2005 Jul; 26(7):1015-22. PubMed ID: 15748781
[TBL] [Abstract][Full Text] [Related]
75. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.
Imahori K; Uchida T
J Biochem; 1997 Feb; 121(2):179-88. PubMed ID: 9089387
[TBL] [Abstract][Full Text] [Related]
76. Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer's disease.
Schmidt ML; Zhukareva V; Newell KL; Lee VM; Trojanowski JQ
Acta Neuropathol; 2001 May; 101(5):518-24. PubMed ID: 11484824
[TBL] [Abstract][Full Text] [Related]
77. An experimental model of Braak's pretangle proposal for the origin of Alzheimer's disease: the role of locus coeruleus in early symptom development.
Ghosh A; Torraville SE; Mukherjee B; Walling SG; Martin GM; Harley CW; Yuan Q
Alzheimers Res Ther; 2019 Jul; 11(1):59. PubMed ID: 31266535
[TBL] [Abstract][Full Text] [Related]
78. Hypersialylation is a common feature of neurofibrillary tangles and granulovacuolar degenerations in Alzheimer's disease and tauopathy brains.
Nagamine S; Yamazaki T; Makioka K; Fujita Y; Ikeda M; Takatama M; Okamoto K; Yokoo H; Ikeda Y
Neuropathology; 2016 Aug; 36(4):333-45. PubMed ID: 26685795
[TBL] [Abstract][Full Text] [Related]
79. Conditional neuronal simian virus 40 T antigen expression induces Alzheimer-like tau and amyloid pathology in mice.
Park KH; Hallows JL; Chakrabarty P; Davies P; Vincent I
J Neurosci; 2007 Mar; 27(11):2969-78. PubMed ID: 17360920
[TBL] [Abstract][Full Text] [Related]
80. A protein kinase, PKN, accumulates in Alzheimer neurofibrillary tangles and associated endoplasmic reticulum-derived vesicles and phosphorylates tau protein.
Kawamata T; Taniguchi T; Mukai H; Kitagawa M; Hashimoto T; Maeda K; Ono Y; Tanaka C
J Neurosci; 1998 Sep; 18(18):7402-10. PubMed ID: 9736660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
